COGT
Cogent Biosciences Inc
30.10$
-0.8%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 15 | Q3 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +5,107.2% | -96.5% | +13.8% | +12.1% | -8.9% | +4.6% | -25.0% | +22.6% | +86.2% | -19.8% | +2.8% | -67.5% | +1,398.8% | -54.0% | -92.5% | -40.9% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | +5,077.3% | – | – | – | – | – | – | – | – | – | -7.8% | -2.7% | +0.2% | -8.3% | -46.0% | -2.5% | +22.1% | -99.7% | -17.6% | +242.9% | +41.7% | +1.5% | +40.6% | +3,725.8% | -74.8% | -22.8% | +68.2% | -29.7% | -7.1% | +34.3% | +1.3% | +1.6% | – | – | +1.7% | – | – | -1.9% | – | – | |
| – | +5,204.2% | -85.4% | +13.8% | +12.1% | -8.9% | +4.6% | -25.0% | +22.6% | +86.2% | -322.3% | – | – | – | -150.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -122.2% | – | – | – | -153.0% | – | – | – | – | – | – | |
| – | – | – | +2.7% | +14.5% | -7.5% | +7.7% | +12.1% | +12.3% | +5.0% | +15.2% | -14.4% | -2.7% | +0.2% | -8.3% | -46.0% | +912.1% | -88.2% | +34.5% | +50.8% | +19.5% | +38.6% | +24.2% | +15.7% | +1.6% | +22.7% | -1.9% | +7.9% | +29.0% | -2.8% | +8.2% | +3.0% | +17.2% | -2.5% | +1.6% | -3.1% | +13.0% | +7.8% | +1.3% | -6.0% | – | |
| – | +322.9% | -94.7% | +2.9% | +36.4% | +8.8% | -26.2% | +86.0% | +19.6% | -13.6% | +21.9% | +22.9% | -11.1% | -1.0% | +36.4% | -23.7% | +99.8% | -4.5% | -14.2% | +6.9% | +2.4% | +2.1% | +16.0% | +7.2% | +8.0% | +1.7% | +2.8% | +14.1% | +15.1% | +0.6% | +2.0% | +4.1% | +16.9% | -0.9% | +1.8% | +12.4% | +7.4% | +66.6% | +18.0% | +12.7% | – | |
| – | +422.7% | -68.3% | +2.7% | +17.1% | -5.2% | +2.3% | +20.6% | +13.6% | +1.5% | +16.3% | -8.2% | -4.6% | -79.4% | +36.4% | -23.7% | +1,773.9% | -78.2% | +11.7% | +35.1% | +14.6% | +29.4% | +22.5% | +14.1% | +2.7% | +18.8% | -1.2% | +8.9% | +26.5% | -2.3% | +7.2% | +3.2% | +17.1% | -2.2% | +1.6% | -0.7% | +12.0% | +17.9% | +4.2% | +0.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -374.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -93.6% | +666.7% | +208.7% | +76.1% | -4.0% | -4.2% | +533.0% | -85.3% | +154.2% | +451.5% | +40.7% | +120.4% | – | – | – | – | – | – | – | – | – | +364.6% | -11.7% | -5.9% | +0.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -365.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -365.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -328.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.